Keyword: Third Rock Ventures
Gilead CMO quits six months after taking job; Allergan taps Pfizer vet as CMO; and Novartis recruits Siemens ethics chief as it reels from scandal.
Third Rock Ventures has named Steven Kafka, former president and chief operating officer of Foundation Medicine, as a new venture partner.
Ambys Medicines will develop cell and gene therapies, as well as drugs, for chronic liver diseases.
Decibel Therapeutics raised $55 million in a series C round and named Vir Biotechnology CEO George Scangos as chair of its board of directors.
Armed with $65 million in series A funding, Celsius will sequence defined patient samples to identify the individual cells responsible for disease.
Armed with $58.5 million from Third Rock, Casma Therapeutics is working on autophagy-boosting treatments for various diseases.
Cedilla is targeting processes that transition cancer-driving proteins from a stable state to a state susceptible to degradation.
Constellation raised $100 million that will bankroll a cancer epigenetics asset through the clinic.
The drug discovery-stage company wants to tune the metabolism of immune cells to change their behavior.
John Davis, who headed early clinical development at Pfizer, joined Magenta Therapeutics.